DC/NK Cell Therapy

Primary Outcomes The primary objective of this trial is to test the safety of formulations containing dendritic cells (DCs) and natural killer (NK) cells cultured in vitro. By evaluating the reactions following the administration of autologous dendritic cells via axillary lymph node injection and natural killer cells via intravenous injection, the study aims to determine the safety profile of these trial products for human use. Secondary Outcomes To verify the success rate of the cultured cell formulations and assess the cytotoxic capacity of natural killer cells in targeting and killing tum

Trial Details

NCT ID
NCT07202611
Phase
PHASE2
Sponsor
National Taiwan University Clinical Trial Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • In vitro culture of autologous dendritic and natural killer cells for the treatment of patients with non-small cell lung cancer
Locations (sample)
  • Huwei, YUNLIN, Taiwan|23.71212,120.4335

Key Eligibility Criteria

  • Eligibility of Participants:
  • o Diagnosed histologically or cytologically with stage IIIB or stage IV non-small cell lung cancer (NSCLC) or patients with recurrence or progressi…
  • Have undergone at least two systemic therapies for advanced NSCLC, including platinum-based chemotherapy, anti-PD-1 therapy, and/or other targeted …
  • At Least One Measurable Lesion:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →